Aptorum (APM) stock underwent a massive rally on Thursday after the biopharmaceutical company announced Clinical Laboratory Evaluation Program (CLEP) Test Approval for blood testing company DiamiR Biosciences’ APOE Genotyping test. This matters to APM shareholders, as the two companies announced merger plans in July 2025. This merger is expected to close in the fourth quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The APOE Genotyping test approval came from the New York State Department of Health (NYSDOH). With it, the company is able to offer its test for a variety of uses, such as blood, buccal swab, saliva, and tissue. This is possible through its Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited clinical laboratory in New York.
DiamiR Biosciences CEO Alidad Mireskandari said, “We are very pleased to have received approval from the NYSDOH for our APOE genotyping test and excited about achieving this regulatory milestone as we continue to build our portfolio of molecular tests for brain health, including neurodegenerative diseases such as mild cognitive impairment and Alzheimer’s disease.”
Aptorum Stock Movement Today
Aptorum stock rallied 115.75% in pre-market trading today, following a 3.79% dip yesterday. The shares have decreased 54.56% year-to-date and 57.96% over the past 12 months. Today’s news came with heavy trading, as some 18 million shares changed hands, compared to a three-month daily average of about 7 million units.
Is Aptorum Stock a Buy, Sell, or Hold?
Turning to Wall Street, coverage of Aptorum stock is thin. Fortunately, TipRanks AI analyst Spark has it covered. Spark rates APM stock a Neutral (41) with no price target. It cites “significant financial difficulties, with declining revenues and persistent losses” as reasons for this stance.
